A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder
Latest Information Update: 11 Nov 2024
At a glance
- Drugs GW 541 (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
Most Recent Events
- 08 Nov 2024 Status changed from discontinued to withdrawn prior to enrolment. (Reason the study was stopped: A decision has been made to prioritize other pipeline programs and terminate this study)
- 19 Dec 2023 Status changed from recruiting to discontinued.
- 02 Aug 2023 Status changed from not yet recruiting to recruiting.